Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXEO NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXEOLexeo Therapeutics$4.74+1.7%$4.39$1.45▼$11.96$255.64M1.36638,597 shs113,458 shsTNXPTonix Pharmaceuticals$32.61-5.7%$41.44$6.76▼$130.00$285.68M1.71.40 million shs674,164 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXEOLexeo Therapeutics-4.90%-5.28%+12.83%+72.59%-61.33%TNXPTonix Pharmaceuticals-8.93%-13.68%-30.43%-6.49%+1.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLXEOLexeo Therapeutics2.5011 of 5 stars3.51.00.00.02.82.50.6TNXPTonix Pharmaceuticals2.8185 of 5 stars3.52.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXEOLexeo Therapeutics 3.00Buy$15.33223.69% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.00114.66% UpsideCurrent Analyst Ratings BreakdownLatest TNXP and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $15.008/15/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $9.007/31/2025LXEOLexeo TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/30/2025LXEOLexeo TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $10.00(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXEOLexeo Therapeutics$650K393.54N/AN/A$3.53 per share1.34TNXPTonix Pharmaceuticals$10.09M28.34N/AN/A$31.82 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)Latest TNXP and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLXEOLexeo TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXEOLexeo TherapeuticsN/A4.434.43TNXPTonix PharmaceuticalsN/A7.537.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXEOLexeo Therapeutics60.67%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipLXEOLexeo Therapeutics5.30%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableTNXP and LXEO HeadlinesRecent News About These CompaniesCarolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) StockAugust 22, 2025 | insidertrades.comSA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXPAugust 20, 2025 | msn.comTonix Pharma Announces FDA Approval of TonmyaAugust 19, 2025 | msn.comTonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)August 19, 2025 | seekingalpha.comTonix Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comFDA Approves New Fibromyalgia Drug, But Tonix Shares SlideAugust 18, 2025 | msn.comTonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 YearsAugust 18, 2025 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA ApprovalAugust 18, 2025 | gurufocus.comFDA Approves New Fibromyalgia Drug, Tonix Shares ClimbAugust 18, 2025 | msn.comThis Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’August 18, 2025 | msn.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLCAugust 18, 2025 | marketbeat.comNoble Financial Has Pessimistic Outlook of TNXP Q3 EarningsAugust 17, 2025 | marketbeat.comFDA approves first new fibromyalgia treatment in over 15 yearsAugust 16, 2025 | thepharmaletter.comTTonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comTonix Secures Fibromyalgia Approval - What Investors Should KnowAugust 16, 2025 | seekingalpha.comTonix Pharma Gains FDA Approval for TonmyaAugust 16, 2025 | msn.comNoble Financial Has Negative Estimate for TNXP Q3 EarningsAugust 16, 2025 | americanbankingnews.comTonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of FibromyalgiaAugust 15, 2025 | manilatimes.netMTonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of TonmyaAugust 15, 2025 | msn.comTonix Pharmaceuticals stock halted ahead of FDA approval newsAugust 15, 2025 | investing.comForm 8K Tonix Pharmaceuticals Holding Corp For: 15 AugustAugust 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP and LXEO Company DescriptionsLexeo Therapeutics NASDAQ:LXEO$4.74 +0.08 (+1.65%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$32.61 -1.98 (-5.72%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Reynolds Consumer Products Stock Price: Insiders Signal a Bottom Ubiquiti's 30% Jump: Why This Was a Turnaround, Not Just a Trend Southern Company: From Nuclear Risk to AI Reward BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Why Sprouts Farmers Market is Buying $1 Billion of Its Own Stock Time for Cleveland-Cliffs Stock to Break Out? Markets Say Yes As the Market Rotates, This Healthcare ETF Is Leading the Way Super Micro Computer Stock Hasn't Priced in Growth Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access